Table 1

Characteristics of patients (n = 1,260)

Characteristic

Number (%) or mean ± SD


Female

1,113 (88.3%)

Menopausal at entry to studya

224 (20.1%)

Menopausal during follow-upa

445 (40.0%)

Race: White

880 (73%)

Black

119 (10%)

Asian

113 (9%)

Other

96 (8%)

Age at first clinic visit (years)

35.0 ± 13.6

Disease duration at first clinic visit (years)

4.0 ± 5.0

SLEDAI-2K at first clinic visitb

9.6 ± 7.7

Age at entry to study (years)

35.4 ± 13.7

Disease duration at entry to study (years)

4.4 ± 6.0

SLEDAI-2K at entry to studyb

8.7 ± 7.0

Hypertension at entry to studyc

190 (15.1%)

Hypercholesterolemia at entry to studye

528 (41.9%)

Diabetes at entry to studyf

30 of 1,223 (2.5%)d

Smoker at entry to studyg

247 of 1,235 (20.0%)d

Corticosteroid use at entry to study

763 of 1,257 (60.7%)d

Antimalarial use at entry to studyh

462 of 1,256 (36.8%)d

Immunosuppressive use at entry to studyi

259 of 1,255 (20.6%)d


SD, standard deviation.

aMenopause defined as a minimum of 12 months of amenorrhea, irrespective of cause.

bScores range from 0 to 105, with higher scores indicating more-active disease.

cDiastolic BP ≥ 90 or systolic BP ≥ 140 mm Hg.

dFor these variables, data were incomplete for a small number of patients. The denominator of the fractions in the second column is the total number of patients from whom the percentage was calculated.

eHypercholesterolemia was defined as cholesterol > 5.2 mmol/L.

fDiabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy.

gSmoking one or more cigarettes per day.

hAntimalarials include chloroquine and hydroxychloroquine.

iImmunosuppressives include methotrexate, azathioprine, mycophenolate mofetil,

cyclosporine, and cyclophosphamide.

Nikpour et al. Arthritis Research & Therapy 2010 12:R125   doi:10.1186/ar3063

Open Data